Biopharmaceutical company Innovent Biologics Inc (HKEX:01801) on Wednesday announced a licensing agreement to develop and commercialise an anti-SIRP-alpha antibody (AL008) for the treatment of cancers in China with biotechnology company Alector Inc (Nasdaq:ALEC).
AL008 is Alector's novel antibody targeting the CD47-SIRP-alpha pathway, a potent survival pathway co-opted by tumours to evade the innate immune system. It is a first-in-class SIRP-alpha inhibitor with a dual mechanism of action that non-competitively antagonises the CD47-SIRP-alpha pathway by inducing the internalisation and degradation of the inhibitory receptor on macrophages to relieve immune suppression while also engaging Fc gamma to promote immuno-stimulatory pathways that drive anti-tumour immunity.
Tumour associated macrophages are associated with poor prognosis in many cancer types and are believed to inhibit the anti-tumour immune response.
Under the agreement, Innovent will lead the development and commercialisation of the molecule in China, including the manufacturing of the product. Alector will lead development of AL008 outside of China.
Financial terms of the agreement were not disclosed.
TuHURA Biosciences acquires Kineta
Tyra Biosciences doses first patient in TYRA-300 Phase 2 study for bladder cancer
HUTCHMED gains China approval for ORPATHYS and TAGRISSO combination in lung cancer
Mabwell and Qilu Pharmaceutical enter licence agreement for Albipagrastim alfa for Injection
FDA approval streamlines access to Bristol Myers Squibb CAR T cell therapies
Biovica secures European patent for biomarker use in immuno-oncology
CARsgen Therapeutics' satri-cel NDA accepted by Chinese regulator
Scancell expands Phase 2 SCOPE trial with new intradermal dosing arm for iSCIB1+
Telix Pharmaceuticals delivers first commercial doses from Belgian manufacturing hub
Innovent presents mazdutide Phase 3 clinical study results at ADA 85th Scientific Sessions
Hoth Therapeutics reports positive interim results for HT-001 topical therapy
Aiforia Technologies launches CE-IVD marked AI solution for breast cancer diagnostics
Stockholders approve proposed merger of TuHURA Biosciences and Kineta
Sarclisa recommended for EU approval in newly diagnosed transplant-eligible multiple myeloma